TAVR market forecast points to $11.44 billion by 2030

The transcatheter aortic valve replacement market is projected to grow from $5.87 billion in 2025 to $11.44 billion by 2030, driven by rising aortic stenosis cases, aging populations and broader use of minimally invasive heart procedures. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - TAVR is becoming a larger part of cardiac care as hospitals and physicians look for less invasive alternatives to open-heart valve surgery. - Rising demand could expand access for patients with aortic stenosis, especially older adults and people considered too high-risk for traditional surgery. - The market’s projected growth signals continued investment in valve technology, imaging and outpatient heart programs.

What happened: - The Business Research Company published a 2026 market report on the global transcatheter aortic valve replacement market. - The report puts the market at $5.87 billion in 2025 and forecasts growth to $6.7 billion in 2026. - The report projects the market will reach $11.44 billion by 2030. - The report also says the market is growing at a 14.1% CAGR from 2025 to 2026 and a 14.3% CAGR through 2030. - The report was released Sept. 1, 2026, from London. - A free sample is available here. - The full report is available here.

The details: - TAVR, also called transcatheter aortic valve implantation, replaces a damaged aortic valve through a less invasive procedure. - The procedure is commonly used for adults who are not good candidates for open-heart valve surgery. - The market growth is tied to higher aortic stenosis prevalence, an aging global population, broader access to cardiac catheterization labs and improvements in valve materials. - The report cites expanding use of TAVR in intermediate-risk patients, demand for longer-lasting valves, structural heart disease programs, improved imaging and a shift toward outpatient procedures. - Emerging trends include wider use of minimally invasive methods, self-expanding valve systems, lower-risk patient categories, advanced imaging and transfemoral access techniques. - TAVR is positioned as an alternative to surgical aortic valve replacement, or SAVR, and is designed to restore blood flow and reduce symptoms caused by valve narrowing. - The American Heart Association reported in May 2024 that more than 12% of elderly Americans have aortic stenosis, which mainly affects people 65 and older. - NICE said in March 2023 that about 1.5% of people over 55 in the UK, or roughly 300,000 people, live with severe aortic stenosis. - NICE also said nearly 200,000 of those patients have symptoms that require medical intervention. - The UK had more than 380,000 patients on waiting lists as of March 2023, adding pressure on cardiac care services.

Between the lines: - The report points to a shift from treating only the highest-risk patients to broader use in intermediate- and lower-risk groups. - Better imaging and procedural precision suggest TAVR is moving from a niche intervention toward a more standardized cardiac treatment. - The focus on outpatient procedures implies health systems are looking to shorten recovery times and lower treatment burden. - North America held the largest market share in 2025, but Asia-Pacific is expected to be the fastest-growing region during the forecast period.

What's next: - The report expects continued growth as more patients qualify for TAVR and as valve technology improves. - Regional expansion in Asia-Pacific could become a major driver of future market share gains. - The report’s 2026 package adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated graphics and tables. - The Business Research Company listed contact details for expert inquiries and follow-up through its website and social channels.

The bottom line: - TAVR is moving from a specialized procedure into a larger, faster-growing global market as aging populations and aortic stenosis cases keep rising.